Atorvastatin Calcium Market By Form (Tablets, Others) , By Application (Hypercholesterolemia, Hyperlipidemia, Others) By Distribution channel (Hospital pharmacies, Drug store & retail pharmacies, Online providers.) : Global Opportunity Analysis and Indus
Description
Atorvastatin Calcium Market By Form (Tablets, Others) , By Application (Hypercholesterolemia, Hyperlipidemia, Others) By Distribution channel (Hospital pharmacies, Drug store & retail pharmacies, Online providers.) : Global Opportunity Analysis and Industry Forecast, 2024-2033
The atorvastatin calcium market was valued at $298.3 million in 2023, and is projected to reach $487.8 million by 2033, growing at a CAGR of 5% from 2024 to 2033.
Atorvastatin calcium is a statin medication, which acts as the first line of treatment for the prevention of cardiovascular diseases. It lowers the cholesterol levels in the blood by inhibiting the enzyme HMG-CoA reductase, which plays a crucial role in cholesterol synthesis in the liver. This medication is effective in lowering low-density lipoprotein (LDL) cholesterol, and can also help to raise high-density lipoprotein (HDL) cholesterol. By managing cholesterol levels, atorvastatin calcium plays a crucial role in preventing heart attacks, strokes, and other serious cardiovascular events.
The growth of the global atorvastatin calcium market is majorly driven by alarming increase in prevalence of cardiovascular diseases. According to the World Heart Federation, cardiovascular diseases are the leading cause of death worldwide as compared to any other cause. Approximately 20.5 million deaths were reported in 2021 across the globe. In addition, surge in geriatric population significantly contributes toward the market growth. This is attributed to the fact that aged individuals are highly susceptible to hypercholesterolemia and related cardiovascular conditions, which, in turn, leads to higher demand for cholesterol-lowering medications like atorvastatin, thereby boosting the market growth. As per AHA 2019 Heart Disease and Stroke Statistical Update, the incidence of cardiovascular diseases was reported to be 77.2% in males and 78.2% in females, from ages 60–79 years. Moreover, rise in sedentary lifestyles and unhealthy eating patterns are leading to higher cholesterol levels among the population, thereby increasing the need for atorvastatin calcium. Furthermore, rise in public awareness of the importance of managing cholesterol levels for overall health and availability of generic versions of atorvastatin calcium boost the growth of the global market. Increase in popularity of combination therapies acts a key trend that is expected to augment the market growth. For instance, the use of atorvastatin calcium in combination with other drugs, such as ezetimibe, is becoming more common to enhance therapeutic outcomes for managing cholesterol levels. However, rise in concerns about potential side effects of atorvastatin calcium such as muscle pain, liver damage, and interactions with other medications can limit its use, which hampers the market growth. In addition, availability of alternative statins and other cholesterol-lowering drugs acts as key deterrent factor of the global market. On the contrary, innovations in drug formulation and delivery systems are enhancing the efficacy and convenience of atorvastatin calcium, which are expected to offer lucrative opportunities for the market growth during the forecast period.
The global atorvastatin calcium market is segmented into form, application, distribution channel, and region. On the basis of form, the market is categorized into tablets and others. By application, it is divided into hypercholesterolemia, hyperlipidemia, and others. Depending on distribution channel, it is categorized into hospital pharmacies, drug store & retail pharmacies, and online providers. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Findings
On the basis of form, the tablets segment dominated the market in 2023, and is is expected to dominate from 2024 to 2033.
By application, hypercholesterolemia is anticipated to be the lucrative segment in the global atorvastatin calcium market in the coming years.
Depending on distribution channel, online pharmacies is projected to emerge as the leading segment by 2033.
Region wise, North America held the largest market share in terms of revenue in 2023, and is expected to dominate the atorvastatin calcium market during the forecast period.
Competition Analysis
Competitive analysis and profiles of the major players in the global atorvastatin calcium market include Mylan Pharmaceuticals Inc., Novartis AG, GlaxoSmithKline plc, Amgen Inc., Sanofi SA, Teva Pharmaceuticals Industries Ltd, Merck and Co. Inc., Bristol-Myers Squibb Company, AstraZeneca Plc., and Pfizer Inc. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to sustain the intense competition and gain a strong foothold in the global market.
Key Market Segments
By Form
Tablets
Others
By Application
Hypercholesterolemia
Hyperlipidemia
Others
By Distribution Channel
Hospital pharmacies
Drug store retail pharmacies
Online providers.
By Region
North America
U.S.
Canada
Mexico
Europe
France
Germany
Italy
Spain
UK
Rest of Europe
Asia-Pacific
China
Japan
India
South Korea
Australia
Rest of Asia-Pacific
LAMEA
Brazil
South Africa
Saudi Arabia
Rest of LAMEA
Key Market Players
Mylan Pharmaceuticals Inc.
Novartis AG
GlaxoSmithKline plc
Amgen Inc.
Sanofi SA
Teva Pharmaceuticals Industries Ltd
Merck and Co. Inc.
Bristol-Myers Squibb Company
AstraZeneca Plc
Pfizer Inc.
Table of Contents
280 Pages
- CHAPTER 1: INTRODUCTION
- 1.1. Report Description
- 1.2. Key Market Segments
- 1.3. Key Benefits
- 1.4. Research Methodology
- 1.4.1. Primary Research
- 1.4.2. Secondary Research
- 1.4.3. Analyst Tools and Models
- CHAPTER 2: EXECUTIVE SUMMARY
- 2.1. CXO Perspective
- CHAPTER 3: MARKET LANDSCAPE
- 3.1. Market Definition and Scope
- 3.2. Key Findings
- 3.2.1. Top Investment Pockets
- 3.2.2. Top Winning Strategies
- 3.3. Porter's Five Forces Analysis
- 3.3.1. Bargaining Power of Suppliers
- 3.3.2. Threat of New Entrants
- 3.3.3. Threat of Substitutes
- 3.3.4. Competitive Rivalry
- 3.3.5. Bargaining Power among Buyers
- 3.4. Market Dynamics
- 3.4.1. Drivers
- 3.4.2. Restraints
- 3.4.3. Opportunities
- CHAPTER 4: ATORVASTATIN CALCIUM MARKET, BY FORM
- 4.1. Market Overview
- 4.1.1 Market Size and Forecast, By Form
- 4.2. Tablets
- 4.2.1. Key Market Trends, Growth Factors and Opportunities
- 4.2.2. Market Size and Forecast, By Region
- 4.2.3. Market Share Analysis, By Country
- 4.3. Others
- 4.3.1. Key Market Trends, Growth Factors and Opportunities
- 4.3.2. Market Size and Forecast, By Region
- 4.3.3. Market Share Analysis, By Country
- CHAPTER 5: ATORVASTATIN CALCIUM MARKET, BY APPLICATION
- 5.1. Market Overview
- 5.1.1 Market Size and Forecast, By Application
- 5.2. Hypercholesterolemia
- 5.2.1. Key Market Trends, Growth Factors and Opportunities
- 5.2.2. Market Size and Forecast, By Region
- 5.2.3. Market Share Analysis, By Country
- 5.3. Hyperlipidemia
- 5.3.1. Key Market Trends, Growth Factors and Opportunities
- 5.3.2. Market Size and Forecast, By Region
- 5.3.3. Market Share Analysis, By Country
- 5.4. Others
- 5.4.1. Key Market Trends, Growth Factors and Opportunities
- 5.4.2. Market Size and Forecast, By Region
- 5.4.3. Market Share Analysis, By Country
- CHAPTER 6: ATORVASTATIN CALCIUM MARKET, BY DISTRIBUTION CHANNEL
- 6.1. Market Overview
- 6.1.1 Market Size and Forecast, By Distribution Channel
- 6.2. Hospital Pharmacies
- 6.2.1. Key Market Trends, Growth Factors and Opportunities
- 6.2.2. Market Size and Forecast, By Region
- 6.2.3. Market Share Analysis, By Country
- 6.3. Drug Store Retail Pharmacies
- 6.3.1. Key Market Trends, Growth Factors and Opportunities
- 6.3.2. Market Size and Forecast, By Region
- 6.3.3. Market Share Analysis, By Country
- 6.4. Online Providers.
- 6.4.1. Key Market Trends, Growth Factors and Opportunities
- 6.4.2. Market Size and Forecast, By Region
- 6.4.3. Market Share Analysis, By Country
- CHAPTER 7: ATORVASTATIN CALCIUM MARKET, BY REGION
- 7.1. Market Overview
- 7.1.1 Market Size and Forecast, By Region
- 7.2. North America
- 7.2.1. Key Market Trends and Opportunities
- 7.2.2. Market Size and Forecast, By Form
- 7.2.3. Market Size and Forecast, By Application
- 7.2.4. Market Size and Forecast, By Distribution Channel
- 7.2.5. Market Size and Forecast, By Country
- 7.2.6. U.S. Atorvastatin Calcium Market
- 7.2.6.1. Market Size and Forecast, By Form
- 7.2.6.2. Market Size and Forecast, By Application
- 7.2.6.3. Market Size and Forecast, By Distribution Channel
- 7.2.7. Canada Atorvastatin Calcium Market
- 7.2.7.1. Market Size and Forecast, By Form
- 7.2.7.2. Market Size and Forecast, By Application
- 7.2.7.3. Market Size and Forecast, By Distribution Channel
- 7.2.8. Mexico Atorvastatin Calcium Market
- 7.2.8.1. Market Size and Forecast, By Form
- 7.2.8.2. Market Size and Forecast, By Application
- 7.2.8.3. Market Size and Forecast, By Distribution Channel
- 7.3. Europe
- 7.3.1. Key Market Trends and Opportunities
- 7.3.2. Market Size and Forecast, By Form
- 7.3.3. Market Size and Forecast, By Application
- 7.3.4. Market Size and Forecast, By Distribution Channel
- 7.3.5. Market Size and Forecast, By Country
- 7.3.6. France Atorvastatin Calcium Market
- 7.3.6.1. Market Size and Forecast, By Form
- 7.3.6.2. Market Size and Forecast, By Application
- 7.3.6.3. Market Size and Forecast, By Distribution Channel
- 7.3.7. Germany Atorvastatin Calcium Market
- 7.3.7.1. Market Size and Forecast, By Form
- 7.3.7.2. Market Size and Forecast, By Application
- 7.3.7.3. Market Size and Forecast, By Distribution Channel
- 7.3.8. Italy Atorvastatin Calcium Market
- 7.3.8.1. Market Size and Forecast, By Form
- 7.3.8.2. Market Size and Forecast, By Application
- 7.3.8.3. Market Size and Forecast, By Distribution Channel
- 7.3.9. Spain Atorvastatin Calcium Market
- 7.3.9.1. Market Size and Forecast, By Form
- 7.3.9.2. Market Size and Forecast, By Application
- 7.3.9.3. Market Size and Forecast, By Distribution Channel
- 7.3.10. UK Atorvastatin Calcium Market
- 7.3.10.1. Market Size and Forecast, By Form
- 7.3.10.2. Market Size and Forecast, By Application
- 7.3.10.3. Market Size and Forecast, By Distribution Channel
- 7.3.11. Rest Of Europe Atorvastatin Calcium Market
- 7.3.11.1. Market Size and Forecast, By Form
- 7.3.11.2. Market Size and Forecast, By Application
- 7.3.11.3. Market Size and Forecast, By Distribution Channel
- 7.4. Asia-Pacific
- 7.4.1. Key Market Trends and Opportunities
- 7.4.2. Market Size and Forecast, By Form
- 7.4.3. Market Size and Forecast, By Application
- 7.4.4. Market Size and Forecast, By Distribution Channel
- 7.4.5. Market Size and Forecast, By Country
- 7.4.6. China Atorvastatin Calcium Market
- 7.4.6.1. Market Size and Forecast, By Form
- 7.4.6.2. Market Size and Forecast, By Application
- 7.4.6.3. Market Size and Forecast, By Distribution Channel
- 7.4.7. Japan Atorvastatin Calcium Market
- 7.4.7.1. Market Size and Forecast, By Form
- 7.4.7.2. Market Size and Forecast, By Application
- 7.4.7.3. Market Size and Forecast, By Distribution Channel
- 7.4.8. India Atorvastatin Calcium Market
- 7.4.8.1. Market Size and Forecast, By Form
- 7.4.8.2. Market Size and Forecast, By Application
- 7.4.8.3. Market Size and Forecast, By Distribution Channel
- 7.4.9. South Korea Atorvastatin Calcium Market
- 7.4.9.1. Market Size and Forecast, By Form
- 7.4.9.2. Market Size and Forecast, By Application
- 7.4.9.3. Market Size and Forecast, By Distribution Channel
- 7.4.10. Australia Atorvastatin Calcium Market
- 7.4.10.1. Market Size and Forecast, By Form
- 7.4.10.2. Market Size and Forecast, By Application
- 7.4.10.3. Market Size and Forecast, By Distribution Channel
- 7.4.11. Rest of Asia-Pacific Atorvastatin Calcium Market
- 7.4.11.1. Market Size and Forecast, By Form
- 7.4.11.2. Market Size and Forecast, By Application
- 7.4.11.3. Market Size and Forecast, By Distribution Channel
- 7.5. LAMEA
- 7.5.1. Key Market Trends and Opportunities
- 7.5.2. Market Size and Forecast, By Form
- 7.5.3. Market Size and Forecast, By Application
- 7.5.4. Market Size and Forecast, By Distribution Channel
- 7.5.5. Market Size and Forecast, By Country
- 7.5.6. Brazil Atorvastatin Calcium Market
- 7.5.6.1. Market Size and Forecast, By Form
- 7.5.6.2. Market Size and Forecast, By Application
- 7.5.6.3. Market Size and Forecast, By Distribution Channel
- 7.5.7. South Africa Atorvastatin Calcium Market
- 7.5.7.1. Market Size and Forecast, By Form
- 7.5.7.2. Market Size and Forecast, By Application
- 7.5.7.3. Market Size and Forecast, By Distribution Channel
- 7.5.8. Saudi Arabia Atorvastatin Calcium Market
- 7.5.8.1. Market Size and Forecast, By Form
- 7.5.8.2. Market Size and Forecast, By Application
- 7.5.8.3. Market Size and Forecast, By Distribution Channel
- 7.5.9. Rest of LAMEA Atorvastatin Calcium Market
- 7.5.9.1. Market Size and Forecast, By Form
- 7.5.9.2. Market Size and Forecast, By Application
- 7.5.9.3. Market Size and Forecast, By Distribution Channel
- CHAPTER 8: COMPETITIVE LANDSCAPE
- 8.1. Introduction
- 8.2. Top Winning Strategies
- 8.3. Product Mapping Of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Top Player Positioning, 2023
- CHAPTER 9: COMPANY PROFILES
- 9.1. Mylan Pharmaceuticals Inc.
- 9.1.1. Company Overview
- 9.1.2. Key Executives
- 9.1.3. Company Snapshot
- 9.1.4. Operating Business Segments
- 9.1.5. Product Portfolio
- 9.1.6. Business Performance
- 9.1.7. Key Strategic Moves and Developments
- 9.2. Novartis AG
- 9.2.1. Company Overview
- 9.2.2. Key Executives
- 9.2.3. Company Snapshot
- 9.2.4. Operating Business Segments
- 9.2.5. Product Portfolio
- 9.2.6. Business Performance
- 9.2.7. Key Strategic Moves and Developments
- 9.3. GlaxoSmithKline Plc
- 9.3.1. Company Overview
- 9.3.2. Key Executives
- 9.3.3. Company Snapshot
- 9.3.4. Operating Business Segments
- 9.3.5. Product Portfolio
- 9.3.6. Business Performance
- 9.3.7. Key Strategic Moves and Developments
- 9.4. Amgen Inc.
- 9.4.1. Company Overview
- 9.4.2. Key Executives
- 9.4.3. Company Snapshot
- 9.4.4. Operating Business Segments
- 9.4.5. Product Portfolio
- 9.4.6. Business Performance
- 9.4.7. Key Strategic Moves and Developments
- 9.5. Sanofi SA
- 9.5.1. Company Overview
- 9.5.2. Key Executives
- 9.5.3. Company Snapshot
- 9.5.4. Operating Business Segments
- 9.5.5. Product Portfolio
- 9.5.6. Business Performance
- 9.5.7. Key Strategic Moves and Developments
- 9.6. Teva Pharmaceuticals Industries Ltd
- 9.6.1. Company Overview
- 9.6.2. Key Executives
- 9.6.3. Company Snapshot
- 9.6.4. Operating Business Segments
- 9.6.5. Product Portfolio
- 9.6.6. Business Performance
- 9.6.7. Key Strategic Moves and Developments
- 9.7. Merck And Co. Inc.
- 9.7.1. Company Overview
- 9.7.2. Key Executives
- 9.7.3. Company Snapshot
- 9.7.4. Operating Business Segments
- 9.7.5. Product Portfolio
- 9.7.6. Business Performance
- 9.7.7. Key Strategic Moves and Developments
- 9.8. Bristol-Myers Squibb Company
- 9.8.1. Company Overview
- 9.8.2. Key Executives
- 9.8.3. Company Snapshot
- 9.8.4. Operating Business Segments
- 9.8.5. Product Portfolio
- 9.8.6. Business Performance
- 9.8.7. Key Strategic Moves and Developments
- 9.9. AstraZeneca Plc
- 9.9.1. Company Overview
- 9.9.2. Key Executives
- 9.9.3. Company Snapshot
- 9.9.4. Operating Business Segments
- 9.9.5. Product Portfolio
- 9.9.6. Business Performance
- 9.9.7. Key Strategic Moves and Developments
- 9.10. Pfizer Inc.
- 9.10.1. Company Overview
- 9.10.2. Key Executives
- 9.10.3. Company Snapshot
- 9.10.4. Operating Business Segments
- 9.10.5. Product Portfolio
- 9.10.6. Business Performance
- 9.10.7. Key Strategic Moves and Developments
- TABLE 1. GLOBAL ATORVASTATIN CALCIUM MARKET, BY FORM, 2024 - 2033 ($MILLION)
- TABLE 2. ATORVASTATIN CALCIUM MARKET FOR TABLETS, BY REGION, 2024 - 2033 ($MILLION)
- TABLE 3. ATORVASTATIN CALCIUM MARKET FOR OTHERS, BY REGION, 2024 - 2033 ($MILLION)
- TABLE 4. GLOBAL ATORVASTATIN CALCIUM MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
- TABLE 5. ATORVASTATIN CALCIUM MARKET FOR HYPERCHOLESTEROLEMIA, BY REGION, 2024 - 2033 ($MILLION)
- TABLE 6. ATORVASTATIN CALCIUM MARKET FOR HYPERLIPIDEMIA, BY REGION, 2024 - 2033 ($MILLION)
- TABLE 7. ATORVASTATIN CALCIUM MARKET FOR OTHERS, BY REGION, 2024 - 2033 ($MILLION)
- TABLE 8. GLOBAL ATORVASTATIN CALCIUM MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
- TABLE 9. ATORVASTATIN CALCIUM MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2024 - 2033 ($MILLION)
- TABLE 10. ATORVASTATIN CALCIUM MARKET FOR DRUG STORE RETAIL PHARMACIES, BY REGION, 2024 - 2033 ($MILLION)
- TABLE 11. ATORVASTATIN CALCIUM MARKET FOR ONLINE PROVIDERS., BY REGION, 2024 - 2033 ($MILLION)
- TABLE 12. ATORVASTATIN CALCIUM MARKET, BY REGION, 2024 - 2033 ($MILLION)
- TABLE 13. NORTH AMERICA ATORVASTATIN CALCIUM MARKET, BY COUNTRY, 2024 - 2033 ($MILLION)
- TABLE 14. NORTH AMERICA ATORVASTATIN CALCIUM MARKET, BY FORM, 2024 - 2033 ($MILLION)
- TABLE 15. NORTH AMERICA ATORVASTATIN CALCIUM MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
- TABLE 16. NORTH AMERICA ATORVASTATIN CALCIUM MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
- TABLE 17. U.S. ATORVASTATIN CALCIUM MARKET, BY FORM, 2024 - 2033 ($MILLION)
- TABLE 18. U.S. ATORVASTATIN CALCIUM MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
- TABLE 19. U.S. ATORVASTATIN CALCIUM MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
- TABLE 20. CANADA ATORVASTATIN CALCIUM MARKET, BY FORM, 2024 - 2033 ($MILLION)
- TABLE 21. CANADA ATORVASTATIN CALCIUM MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
- TABLE 22. CANADA ATORVASTATIN CALCIUM MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
- TABLE 23. MEXICO ATORVASTATIN CALCIUM MARKET, BY FORM, 2024 - 2033 ($MILLION)
- TABLE 24. MEXICO ATORVASTATIN CALCIUM MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
- TABLE 25. MEXICO ATORVASTATIN CALCIUM MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
- TABLE 26. EUROPE ATORVASTATIN CALCIUM MARKET, BY COUNTRY, 2024 - 2033 ($MILLION)
- TABLE 27. EUROPE ATORVASTATIN CALCIUM MARKET, BY FORM, 2024 - 2033 ($MILLION)
- TABLE 28. EUROPE ATORVASTATIN CALCIUM MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
- TABLE 29. EUROPE ATORVASTATIN CALCIUM MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
- TABLE 30. FRANCE ATORVASTATIN CALCIUM MARKET, BY FORM, 2024 - 2033 ($MILLION)
- TABLE 31. FRANCE ATORVASTATIN CALCIUM MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
- TABLE 32. FRANCE ATORVASTATIN CALCIUM MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
- TABLE 33. GERMANY ATORVASTATIN CALCIUM MARKET, BY FORM, 2024 - 2033 ($MILLION)
- TABLE 34. GERMANY ATORVASTATIN CALCIUM MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
- TABLE 35. GERMANY ATORVASTATIN CALCIUM MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
- TABLE 36. ITALY ATORVASTATIN CALCIUM MARKET, BY FORM, 2024 - 2033 ($MILLION)
- TABLE 37. ITALY ATORVASTATIN CALCIUM MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
- TABLE 38. ITALY ATORVASTATIN CALCIUM MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
- TABLE 39. SPAIN ATORVASTATIN CALCIUM MARKET, BY FORM, 2024 - 2033 ($MILLION)
- TABLE 40. SPAIN ATORVASTATIN CALCIUM MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
- TABLE 41. SPAIN ATORVASTATIN CALCIUM MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
- TABLE 42. UK ATORVASTATIN CALCIUM MARKET, BY FORM, 2024 - 2033 ($MILLION)
- TABLE 43. UK ATORVASTATIN CALCIUM MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
- TABLE 44. UK ATORVASTATIN CALCIUM MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
- TABLE 45. REST OF EUROPE ATORVASTATIN CALCIUM MARKET, BY FORM, 2024 - 2033 ($MILLION)
- TABLE 46. REST OF EUROPE ATORVASTATIN CALCIUM MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
- TABLE 47. REST OF EUROPE ATORVASTATIN CALCIUM MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
- TABLE 48. ASIA-PACIFIC ATORVASTATIN CALCIUM MARKET, BY COUNTRY, 2024 - 2033 ($MILLION)
- TABLE 49. ASIA-PACIFIC ATORVASTATIN CALCIUM MARKET, BY FORM, 2024 - 2033 ($MILLION)
- TABLE 50. ASIA-PACIFIC ATORVASTATIN CALCIUM MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
- TABLE 51. ASIA-PACIFIC ATORVASTATIN CALCIUM MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
- TABLE 52. CHINA ATORVASTATIN CALCIUM MARKET, BY FORM, 2024 - 2033 ($MILLION)
- TABLE 53. CHINA ATORVASTATIN CALCIUM MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
- TABLE 54. CHINA ATORVASTATIN CALCIUM MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
- TABLE 55. JAPAN ATORVASTATIN CALCIUM MARKET, BY FORM, 2024 - 2033 ($MILLION)
- TABLE 56. JAPAN ATORVASTATIN CALCIUM MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
- TABLE 57. JAPAN ATORVASTATIN CALCIUM MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
- TABLE 58. INDIA ATORVASTATIN CALCIUM MARKET, BY FORM, 2024 - 2033 ($MILLION)
- TABLE 59. INDIA ATORVASTATIN CALCIUM MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
- TABLE 60. INDIA ATORVASTATIN CALCIUM MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
- TABLE 61. SOUTH KOREA ATORVASTATIN CALCIUM MARKET, BY FORM, 2024 - 2033 ($MILLION)
- TABLE 62. SOUTH KOREA ATORVASTATIN CALCIUM MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
- TABLE 63. SOUTH KOREA ATORVASTATIN CALCIUM MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
- TABLE 64. AUSTRALIA ATORVASTATIN CALCIUM MARKET, BY FORM, 2024 - 2033 ($MILLION)
- TABLE 65. AUSTRALIA ATORVASTATIN CALCIUM MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
- TABLE 66. AUSTRALIA ATORVASTATIN CALCIUM MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
- TABLE 67. REST OF ASIA-PACIFIC ATORVASTATIN CALCIUM MARKET, BY FORM, 2024 - 2033 ($MILLION)
- TABLE 68. REST OF ASIA-PACIFIC ATORVASTATIN CALCIUM MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
- TABLE 69. REST OF ASIA-PACIFIC ATORVASTATIN CALCIUM MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
- TABLE 70. LAMEA ATORVASTATIN CALCIUM MARKET, BY COUNTRY, 2024 - 2033 ($MILLION)
- TABLE 71. LAMEA ATORVASTATIN CALCIUM MARKET, BY FORM, 2024 - 2033 ($MILLION)
- TABLE 72. LAMEA ATORVASTATIN CALCIUM MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
- TABLE 73. LAMEA ATORVASTATIN CALCIUM MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
- TABLE 74. BRAZIL ATORVASTATIN CALCIUM MARKET, BY FORM, 2024 - 2033 ($MILLION)
- TABLE 75. BRAZIL ATORVASTATIN CALCIUM MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
- TABLE 76. BRAZIL ATORVASTATIN CALCIUM MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
- TABLE 77. SOUTH AFRICA ATORVASTATIN CALCIUM MARKET, BY FORM, 2024 - 2033 ($MILLION)
- TABLE 78. SOUTH AFRICA ATORVASTATIN CALCIUM MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
- TABLE 79. SOUTH AFRICA ATORVASTATIN CALCIUM MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
- TABLE 80. SAUDI ARABIA ATORVASTATIN CALCIUM MARKET, BY FORM, 2024 - 2033 ($MILLION)
- TABLE 81. SAUDI ARABIA ATORVASTATIN CALCIUM MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
- TABLE 82. SAUDI ARABIA ATORVASTATIN CALCIUM MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
- TABLE 83. REST OF LAMEA ATORVASTATIN CALCIUM MARKET, BY FORM, 2024 - 2033 ($MILLION)
- TABLE 84. REST OF LAMEA ATORVASTATIN CALCIUM MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
- TABLE 85. REST OF LAMEA ATORVASTATIN CALCIUM MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
- TABLE 86. MYLAN PHARMACEUTICALS INC.: KEY EXECUTIVES
- TABLE 87. MYLAN PHARMACEUTICALS INC.: COMPANY SNAPSHOT
- TABLE 88. MYLAN PHARMACEUTICALS INC.: OPERATING SEGMENTS
- TABLE 89. MYLAN PHARMACEUTICALS INC.: PRODUCT PORTFOLIO
- TABLE 90. MYLAN PHARMACEUTICALS INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 91. NOVARTIS AG: KEY EXECUTIVES
- TABLE 92. NOVARTIS AG: COMPANY SNAPSHOT
- TABLE 93. NOVARTIS AG: OPERATING SEGMENTS
- TABLE 94. NOVARTIS AG: PRODUCT PORTFOLIO
- TABLE 95. NOVARTIS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 96. GLAXOSMITHKLINE PLC: KEY EXECUTIVES
- TABLE 97. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
- TABLE 98. GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
- TABLE 99. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
- TABLE 100. GLAXOSMITHKLINE PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 101. AMGEN INC.: KEY EXECUTIVES
- TABLE 102. AMGEN INC.: COMPANY SNAPSHOT
- TABLE 103. AMGEN INC.: OPERATING SEGMENTS
- TABLE 104. AMGEN INC.: PRODUCT PORTFOLIO
- TABLE 105. AMGEN INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 106. SANOFI SA: KEY EXECUTIVES
- TABLE 107. SANOFI SA: COMPANY SNAPSHOT
- TABLE 108. SANOFI SA: OPERATING SEGMENTS
- TABLE 109. SANOFI SA: PRODUCT PORTFOLIO
- TABLE 110. SANOFI SA: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 111. TEVA PHARMACEUTICALS INDUSTRIES LTD: KEY EXECUTIVES
- TABLE 112. TEVA PHARMACEUTICALS INDUSTRIES LTD: COMPANY SNAPSHOT
- TABLE 113. TEVA PHARMACEUTICALS INDUSTRIES LTD: OPERATING SEGMENTS
- TABLE 114. TEVA PHARMACEUTICALS INDUSTRIES LTD: PRODUCT PORTFOLIO
- TABLE 115. TEVA PHARMACEUTICALS INDUSTRIES LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 116. MERCK AND CO. INC.: KEY EXECUTIVES
- TABLE 117. MERCK AND CO. INC.: COMPANY SNAPSHOT
- TABLE 118. MERCK AND CO. INC.: OPERATING SEGMENTS
- TABLE 119. MERCK AND CO. INC.: PRODUCT PORTFOLIO
- TABLE 120. MERCK AND CO. INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 121. BRISTOL-MYERS SQUIBB COMPANY: KEY EXECUTIVES
- TABLE 122. BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT
- TABLE 123. BRISTOL-MYERS SQUIBB COMPANY: OPERATING SEGMENTS
- TABLE 124. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO
- TABLE 125. BRISTOL-MYERS SQUIBB COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 126. ASTRAZENECA PLC: KEY EXECUTIVES
- TABLE 127. ASTRAZENECA PLC: COMPANY SNAPSHOT
- TABLE 128. ASTRAZENECA PLC: OPERATING SEGMENTS
- TABLE 129. ASTRAZENECA PLC: PRODUCT PORTFOLIO
- TABLE 130. ASTRAZENECA PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 131. PFIZER INC.: KEY EXECUTIVES
- TABLE 132. PFIZER INC.: COMPANY SNAPSHOT
- TABLE 133. PFIZER INC.: OPERATING SEGMENTS
- TABLE 134. PFIZER INC.: PRODUCT PORTFOLIO
- TABLE 135. PFIZER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- FIGURE 1. GLOBAL ATORVASTATIN CALCIUM MARKET, 2024 - 2033
- FIGURE 2. SEGMENTATION OF ATORVASTATIN CALCIUM MARKET, 2024 - 2033
- FIGURE 3. TOP INVESTMENT POCKET IN ATORVASTATIN CALCIUM MARKET
- FIGURE 4. MODERATE BARGAINING POWER OF BUYERS
- FIGURE 5. MODERATE BARGAINING POWER OF SUPPLIERS
- FIGURE 6. MODERATE THREAT OF NEW ENTRANTS
- FIGURE 7. LOW THREAT OF SUBSTITUTION
- FIGURE 8. HIGH COMPETITIVE RIVALRY
- FIGURE 9. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALATORVASTATIN CALCIUM MARKET
- FIGURE 10. GLOBAL ATORVASTATIN CALCIUM MARKET SEGMENTATION, BY FORM
- FIGURE 11. ATORVASTATIN CALCIUM MARKET FOR TABLETS, BY COUNTRY, 2024 - 2033 ($MILLION)
- FIGURE 12. ATORVASTATIN CALCIUM MARKET FOR OTHERS, BY COUNTRY, 2024 - 2033 ($MILLION)
- FIGURE 13. GLOBAL ATORVASTATIN CALCIUM MARKET SEGMENTATION, BY APPLICATION
- FIGURE 14. ATORVASTATIN CALCIUM MARKET FOR HYPERCHOLESTEROLEMIA, BY COUNTRY, 2024 - 2033 ($MILLION)
- FIGURE 15. ATORVASTATIN CALCIUM MARKET FOR HYPERLIPIDEMIA, BY COUNTRY, 2024 - 2033 ($MILLION)
- FIGURE 16. ATORVASTATIN CALCIUM MARKET FOR OTHERS, BY COUNTRY, 2024 - 2033 ($MILLION)
- FIGURE 17. GLOBAL ATORVASTATIN CALCIUM MARKET SEGMENTATION, BY DISTRIBUTION CHANNEL
- FIGURE 18. ATORVASTATIN CALCIUM MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2024 - 2033 ($MILLION)
- FIGURE 19. ATORVASTATIN CALCIUM MARKET FOR DRUG STORE RETAIL PHARMACIES, BY COUNTRY, 2024 - 2033 ($MILLION)
- FIGURE 20. ATORVASTATIN CALCIUM MARKET FOR ONLINE PROVIDERS., BY COUNTRY, 2024 - 2033 ($MILLION)
- FIGURE 21. TOP WINNING STRATEGIES, BY YEAR, 2021-2023*
- FIGURE 22. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2021-2023*
- FIGURE 23. TOP WINNING STRATEGIES, BY COMPANY, 2021-2023*
- FIGURE 24. PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 25. COMPETITIVE DASHBOARD
- FIGURE 26. COMPETITIVE HEATMAP: ATORVASTATIN CALCIUM MARKET
- FIGURE 27. TOP PLAYER POSITIONING, 2023
- FIGURE 28. MYLAN PHARMACEUTICALS INC.: NET SALES, 2021-2023 ($MILLION)
- FIGURE 29. MYLAN PHARMACEUTICALS INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 30. MYLAN PHARMACEUTICALS INC.: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 31. NOVARTIS AG: NET SALES, 2021-2023 ($MILLION)
- FIGURE 32. NOVARTIS AG: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 33. NOVARTIS AG: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 34. GLAXOSMITHKLINE PLC: NET SALES, 2021-2023 ($MILLION)
- FIGURE 35. GLAXOSMITHKLINE PLC: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 36. GLAXOSMITHKLINE PLC: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 37. AMGEN INC.: NET SALES, 2021-2023 ($MILLION)
- FIGURE 38. AMGEN INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 39. AMGEN INC.: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 40. SANOFI SA: NET SALES, 2021-2023 ($MILLION)
- FIGURE 41. SANOFI SA: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 42. SANOFI SA: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 43. TEVA PHARMACEUTICALS INDUSTRIES LTD: NET SALES, 2021-2023 ($MILLION)
- FIGURE 44. TEVA PHARMACEUTICALS INDUSTRIES LTD: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 45. TEVA PHARMACEUTICALS INDUSTRIES LTD: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 46. MERCK AND CO. INC.: NET SALES, 2021-2023 ($MILLION)
- FIGURE 47. MERCK AND CO. INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 48. MERCK AND CO. INC.: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 49. BRISTOL-MYERS SQUIBB COMPANY: NET SALES, 2021-2023 ($MILLION)
- FIGURE 50. BRISTOL-MYERS SQUIBB COMPANY: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 51. BRISTOL-MYERS SQUIBB COMPANY: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 52. ASTRAZENECA PLC: NET SALES, 2021-2023 ($MILLION)
- FIGURE 53. ASTRAZENECA PLC: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 54. ASTRAZENECA PLC: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 55. PFIZER INC.: NET SALES, 2021-2023 ($MILLION)
- FIGURE 56. PFIZER INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 57. PFIZER INC.: REVENUE SHARE, BY REGION, 2023 (%)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
